 |
Molecular model of the drug Sutent, formerly known as SU-11248 (Image: gistsupport/VNE) |
The exceptional efficacy of Sutent in clinical trials for advanced stomach and kidney cancers has prompted the FDA to shorten the trial period and allow early treatment for patients.
Sutent works by inhibiting blood flow and essential nutrients needed to nourish cancer cells.
Clinical trials have shown that with a dosage of one Sutent pill per day, tumor tissues have shrunk and slowed their progression in cancer patients. The side effects of this medication include diarrhea, skin discoloration, dry mouth, and decreased taste sensation.
According to TTXVN, the United States Food and Drug Administration (FDA) has recently approved the new drug Sutent, produced by the American pharmaceutical company Pfizer, for the treatment of kidney cancer and stomach cancer.
